Background {#Sec1}
==========

With improved survival for primary bone malignancies resulting from modern chemotherapy regimens, the development of limb-salvage procedures has flourished. In the lower extremity, where the primary function of the skeleton is to support body weight and allow ambulation, reconstruction of bone defects is of major interest to preserve its function. Many surgical options for the reconstruction and stabilization of massive bone defects around the knee joint have been described and include biologic options with autografts and allografts or the use of tumor endoprostheses \[[@CR1]\]. The evolution of distal femoral replacements (DFR) has gone from custom-made devices to modern modular implants and more recently, to the addition of antibacterial coatings \[[@CR2]\].

Apart from bone defects caused by tumors, failed revision arthroplasty has become another challenging indication for the use of DFR. Although results of current tumor megaprostheses have been discussed consistently in recent literature \[[@CR3]--[@CR14]\], various aspects affecting the outcome have not been uncovered yet: It is still unclear which patients are at risk to experience low functional outcome after this procedure. Hence, it is not well understood whether complications after DFR depend on the indication for surgery or, for instance, the patients' age. Further, there have been but few reports that evaluated functional outcomes after these reconstructions with the modular Munich-Luebeck (MML) knee prosthesis for various indications \[[@CR15], [@CR16]\].

Therefore, the aim of the present study was to report the outcomes and complications in patients treated with MML DFR from one orthopedic center. We asked the following questions: (1) What are the functional outcomes of modular knee replacements with DFR? (2) Do complications vary with the indication for this procedure (malignant disease vs. revision arthroplasty)?

Methods {#Sec2}
=======

Approval of the institutional review board and written consent from each subject prior to inclusion were obtained before initiating the study. We retrospectively reviewed our institution's database for patients who underwent reconstruction of the distal femur and/or proximal tibia due to tumors or failed revision arthroplasties from January 2002 to January 2015. Reconstruction of the defect was carried out with the modular knee prosthesis MML (ESKA/Orthodynamics, Luebeck, Germany) comprising a fully constrained total knee system with the possibility to augment distal femoral defects. We identified 129 patients (male/female = 55/74) with 129 DFRs. Forty-seven of the 129 patients had died at the time of our chart review, and another 46 were excluded from clinical investigation because they were not able to present at our clinic or declined to participate in the clinical follow-up part of this study. Nevertheless, they gave consent to be included in the prosthesis survival analysis. Thus, 36 patients were included in our study for clinical investigation and 82 patients for the survival analysis (Fig. [1](#Fig1){ref-type="fig"}). Demographic data of the cohort are given in Table [1](#Tab1){ref-type="table"}. Patients were subdivided into groups A and B according to the indication for DFR: malignant musculoskeletal disease (group A; *n* = 20, mean age 46,2 ± 22,1 years) or failed revision arthroplasty (group B; *n* = 16, mean age 71,0 ± 13,3 years). Surgical details, follow-up intervals and examinations, complications, and functional scores for massive bone defect reconstruction (Musculoskeletal Tumor Society \[MSTS\] score) were recorded. Additionally, functional scores evaluating results after knee surgeries (American Knee Society Score \[AKSS\], Oxford Knee Score \[OKS\], Western Ontario and McMaster Universities Osteoarthritis Index \[WOMAC\], Toronto Extremity Salvage Score \[TESS\]), pain (numeric pain rating scale \[NRS\]), and overall health-related-quality of life (12-Item Short-Form \[SF-12\] Health Survey) were analyzed. Complications were classified according to the five modes of failure for megaprostheses established by Henderson et al. (Table [2](#Tab2){ref-type="table"}) \[[@CR17], [@CR18]\].Fig. 1Total cohort and patients included in the study groups Table 1Categorization of failure modes according to *Henderson* \[[@CR17]\]CategoryTypeSubgroupMechanicalI. Soft tissue failureA: instability due to tendon/muscle rupture\
B: aseptic wound dehiscenceII. Aseptic looseningA: \<2 years after implantation\
B:\>2 years after implantationIII. Structural failureA: prosthetic failure\
B: periprosthetic fractureNon-mechanicalIV. Periprosthetic infectionA: \<2 years after implantation\
B:\>2 years after implantationV. Tumor progression with contamination of prosthesisA: soft tissue tumor\
B: bone tumor Table 2MSTS score with subdomains of both groupsGeneral criteriaLimb-specific criteriaScorePainFunctionGeneral acceptanceSupportsWalking abilityGaitGroup APreoperative3,23,13,13,74,23,821 ± 8Postoperative3,53,02,63,03,12,217 ± 8*p*-value0,80,860,740,640,510,520,14Group BPreoperative2,252,02,63,43,12,216 ± 7Postoperative2,91,91,51,81,91,612 ± 9*p*-value0,60,830,430,090,080,320,23

Statistics {#Sec3}
----------

Kaplan--Meier survivorship analysis of 82 prosthetic devices was performed. All data are reported as the mean (with standard deviation) or percentage, where applicable. Comparisons of patient-reported outcomes were performed using a *t*-test for unpaired samples. Where applicable, the Mann--Whitney *U* test for independent samples was used. Statistical significance was set at *p* \< 0.05. Correlations between age and clinical outcome was performed with linear regression analysis and six age-matched groups (*n* = 6 per group), and the r^2^ value is reported. Statistical analysis was performed using SPSS 2.0 (IBM, Armonk, NY, USA).

Results {#Sec4}
=======

Clinical outcome {#Sec5}
----------------

Overall, patients in our series had a mean numeric pain rating scale of 4.8 preoperatively (group A: 3.6; group B: 6.2; *p* \< 0.05) and 3.4 after DFR (group A: 2.3, group B: 4.9; *p* \< 0.05). The differences between pre- and postoperative NRS values within each group were not significant (group A: *p* = 0.283; group B: *p* = 0.304).

The mean preoperative MSTS score of group A (20.9 ± 7.9) was significantly higher (*p* \< 0.05) than in group B (15.5 ± 6.9) (Table [3](#Tab3){ref-type="table"}). Postoperatively, both groups showed a reduction of MSTS score compared to their preoperative value (group A: 17.2 ± 8.1; group B: 11.6 ± 8.8). The difference of these postoperative values was not significant (*p* = 0.138) between the groups.Table 3Functional outcome results of both groupsScoresGroup A \[Value, SD\]Group B \[Value, SD\]*p*-valueWOMAC26,2 ± 20,849,6 ± 26,20,011AKS74,0 ± 23,046,9 ± 32,10,012TESS80,2 ± 26,546,7 ± 33,40.008OKS31,5 ± 11,119,3 ± 12,40.008SF-12 Physical subdomain39,6 ± 11,331,9 ± 10,00.06 Mental subdomain49,9 ± 9,838,8 ± 11,90.006*p* \< 0.05 = significant; SD: standard deviationWOMAC (Western Ontario and McMaster Universities Osteoarthritis Index): 96 (poor)-0 (very good)AKS (American Knee Society Score): \<60: poor; 60 -- 69: fair; 70--79: good; 80--100: excellentTESS (Toronto Extremity Salvage Score): 0 (poor)-100 (very good)OKS (Oxford knee score): \<19: poor; 20--29: fair; 30--39: good; 40--48: very goodSF-12 (Short Form 12 Health Survey): healthy controls \> 50

Clinical outcome data computed by AKSS, TESS, OKS, WOMAC, as well as results of SF-12 analysis are provided in Table [3](#Tab3){ref-type="table"}. Correlation of functional outcome values of AKSS, TESS, NRS, and OKS showed high dependence on the age with r^2^ \> 0.8 for all four scores: the higher the age, the worse the clinical outcome (Table [4](#Tab4){ref-type="table"}). Physical subdomain of SF-12 also showed an age-dependent correlation, with all values being worse than the general population. On the other hand, the mental subdomain was not significantly reduced in comparison to the general population up to group 3 (mean age, 54.6 years); group 4 to 6 showed significantly reduced values. Analyses of the age-dependent correlation of clinical outcome evaluated with OKS and AKSS showed that patients in group B had a more pronounced deterioration of function than patients in group A; however, this difference was not statistically significant.Table 4Comparison of age-matched groups and clinical outcomeGroup (n. of patients)Mean age (years)AKSOKSTESSSF 12\
KSSSF12\
PSSNRS1 (6)23,590,00880,8951,4150,380,832 (6)36,678,33600,6537,8048,292,333 (6)54,660,00500,5834,0449,032,674 (6)69,058,33510,5633,3545,313,835 (6)75,733,33370,3328,7239,135,676 (6)83,351,43360,4030,3736,035,86

Complications {#Sec6}
-------------

Eighty-two patients were analyzed for complications, of which 53 patients showed 75 complications, and 29 patients had no complications. Further analysis revealed 36 patients with one complication, 13 patients with two, three patients with three, and one patient with four. Comparing the rate of complications between both groups, 32 patients with tumors had 45 complications, and 21 patients with failed arthroplasty had 30 complications (Table [5](#Tab5){ref-type="table"}).Table 5Number of complications in the present series as classified according to Henderson et al. \[[@CR17]\]Type (Henderson)Number of complicationsGroup A (Tumor)Group B (Failed arthroplasty)Type I17 (22.7%)11 (24.4%)6 (20%) A10 (13.3%)5 (11.1%)5 (16.7%) B7 (9.3%)6 (13.3%)1 (3.3%)Type II15 (20%)8 (17.8%)7 (23.3%) A7 (9.3%)4 (8.9%)3 (10%) B8 (10.7%)4 (8.9%)4 (13.3%)Type III28 (37.3%)18 (40%)10 (33.3%) A17 (22.7%)13 (28.9%)4 (13.3%) B11 (14.7%)5 (11.1%)6 (20%)Type IV13 (17.3%)6 (13.3%)7 (23.3%) A11 (14.7%)5 (11.1%)6 (20%) B2 (2.7%)1 (2.2%)1 (3.3%)Type V2 (2.7%)2 (4.4%)0 (0%) A1 (1.3%)1 (2.2%)0 (0%) B1 (1.3%)1 (2.2%)0 (0%)Total75 (100%)45 (100%)30 (100%)% of total complications are put in parentheses

Implant survival analysis {#Sec7}
-------------------------

Eighty-two patients were included in the survivorship analysis. Implant failure was defined as partial or complete exchange of the megaprosthesis or amputation due to implant-related complications. Mean implant survival was 81.8 ± 7.3 months, with 53% of all patients living with the initially implanted device after 60 months. Implants of patients with tumors had a mean survival of 81.2 ± 9.7 months, while those of patients with failed arthroplasty showed a mean survival of 76.5 ± 9.7 months (*p* = 0.958).

Discussion {#Sec8}
==========

To our best knowledge, this is the largest case series of DFR with the MML-System published to date.

Our study has several limitations that must be taken into consideration. First, the sample size in our report is small in terms of statistical analysis, and the analysis is retrospective. Second, there is no comparison between defect reconstruction with DFR and other surgical treatments such as allograft reconstruction or amputation. Third, the procedures were performed by multiple surgeons, so individual surgical techniques might have affected the overall results.

To address our first and second questions, we detected a high overall complication rate of 64%, considerably higher than the complication rate after standard revision arthroplasty of 24.1% reported by Werner et al. in a large cohort of 28,812 patients \[[@CR1]\].

The main local complications in our cohort were Henderson type III (structural failure) and type I (soft tissue failure) followed by Henderson type II (aseptic loosening) and type IV (deep infections). Regarding type III complications, problems associated with the prosthesis (type IIIA) were more frequent than periprosthetic fractures (type IIIB).

Starting in the late 1990s, bolt breakage at the level of the hinged knee module was reported in the first-generation design of the MML prosthesis. Hence, the design was changed and the second-generation prostheses had strengthened central axis bolts \[[@CR16]\]. In our cohort, only second generation prostheses were implanted. Nevertheless, some of the patients in the tumor group of our cohort had up to three incidences of bolt breakage, none necessitating prosthesis exchange. A possible explanation for tumor patients exhibiting prosthesis failure more frequently may be their lower mean age of 46 years. Younger patients after primary reconstruction are more likely to undertake normal activities including sports than older people with a history of revision arthroplasty.

In our cohort, patients with DFR after tumor resection were more likely to have wound complications than patients with DFR after failed arthroplasty. Due to different surgical principles between the two groups, local wound problems may occur more often after radical tumor surgery, as it is a limb-salvage operation with the primary aim of tumor-free survival. We assume that the extensive resection of a tumor is a predisposing factor for wound complications because of compromised blood circulation in the remaining soft tissue. The most frequent Henderson type IB complication in our cohort was rupture of the patellar tendon. The probability for this complication did not differ between the two groups. This complication is inconsistently discussed in literature: While Bus et al. reported no rupture over 15 years using the Modular Universal Tumor And Revision System (MUTARS), Ruggieri et al. described this problem as one of the main complications of DFR in their cohort \[[@CR2], [@CR3]\].

Our results concerning type IV failure rates are comparable to cohorts of other research groups \[[@CR2], [@CR7]--[@CR9]\]. The higher rate among failed arthroplasty cases might be a result of the number of previous surgeries in that cohort leading to impaired tissue coverage.

Henderson type II (aseptic loosening) occurred in 17.8% cases after primary reconstruction and in 23.3% cases after failed revision arthroplasty. This is comparable to most long-term follow-up studies where this type of failure was reported at a rate of 2.4--15.4% for cemented \[[@CR13], [@CR18]--[@CR20]\] and 0--8% for cementless implants \[[@CR21]--[@CR24]\].

We did not find significant differences concerning the likelihood of complications in our groups; this may be caused by the limited number of patients and resulting lack of statistical power. Mean implant survival was comparable in both groups: 81.8 ± 7.3 months (tumor) vs. 76.5 ± 9.7 months (arthroplasty). Data from the literature show heterogeneous 5- and 10-year survival rates, ranging from 25--93% (Table [6](#Tab6){ref-type="table"}).Table 6Literature overview on distal femoral replacement after tumor surgeryStudyNo. of implantsMean follow-up (years)Functional AssessmentImplant survival5 years10 years15 yearsBatta et al. \[[@CR14]\]6910.4N/A73%65%55%Biau et al.^a^ \[[@CR13]\]915.2N/A76%45%29%Bickels et al. \[[@CR12]\]1107.8N/A93%88%N/ABus et al.^a^ \[[@CR25]\]1107.2N/A89% at follow-upCoathup et al. \[[@CR10]\]618.5N/A89%84%75%Griffin et al.^a^ \[[@CR9]\]996.1N/A82%N/AN/AKinkel et al.^a^ \[[@CR8]\]773.8N/A57%N/AN/AMorgan et al.^a^ \[[@CR7]\]1054.8N/A73%59%N/AMyers et al.\[[@CR6]\]33512N/A83%67%51%Pala et al.^a^ \[[@CR5]\]2474N/A70% at 4 years48% at 8 yearsPlötz et al.^a^ \[[@CR15]\]604.9N/A34%25%N/ARuggieri et al.^b^ \[[@CR4]\]66911N/AN/A80%55% at 20 yearsSchwartz et al. \[[@CR3]\]1868N/AN/A77%N/A^a^Study reports on distal femoral and proximal tibial replacement^b^Study reports on distal femoral, total femoral, and proximal tibial replacement

Our results showed a reduction of pain using the NRS score from 4.8 preoperatively to 3.4 postoperatively. Patients in the failed arthroplasty group had significantly higher preoperative pain levels than the tumor group. This is important because according to Robinson et al., a low preoperative quality of life correlates with lower postoperative function \[[@CR10]\].

Functional outcome measurement with respect to the MSTS score, the only established score for evaluation of massive bone reconstructions, revealed significantly higher average preoperative values in the tumor group than in the revision arthroplasty group. Additionally, there was a significant difference of 25 years in the mean ages of the two groups. This is the most influential factor on MSTS score differences between the groups as shown in linear regression analysis. We analyzed all relevant clinical scores for the knee (AKSS, TESS, OKS, WOMAC) as well as the SF-12. Our main finding indicated that the functional outcome after DFR is strongly related to the age of the patient. We compared age-matched groups and clinical outcome in AKSS, OKS, TESS, and NRS. With an r^2^ \> 0.8, we demonstrate that high age is related to worse clinical outcomes after DFR. Pala et al. stated that the preoperative quality of life and preoperative function are crucial factors for the outcome in revision hip arthroplasty \[[@CR5]\]. We observed similar effects in our revision arthroplasty group. Additionally, the mental and physical condition scaled in the SF-12 is strongly age related, with better results among younger patients. Review of the literature regarding functional outcome measures after DFR revealed data given in Table [7](#Tab7){ref-type="table"}.Table 7Literature overview on distal femoral replacement after tumor surgeryStudyNo. of implantsMean follow-up (months)Postoperative Functional AssessmentImplant survivalBack et al. \[[@CR26]\]3258KSS: 9584%Barrack et al. \[[@CR27]\]1651KSS: 13194%Barrack et al. \[[@CR28]\]2358KSS: 13396%Berend et al. \[[@CR29]\]3946KSS: 12387%Jones et al. \[[@CR30]\]1647KSS: 13796%Jones et al. \[[@CR31]\]3049KSS: 13488%Lombardi et al. \[[@CR32]\]11325HSS: 7385%Petrou et al. \[[@CR33]\]100132KSS: 16387%Pour et al. \[[@CR34]\]4450KSS 11770%Pradham et al. \[[@CR35]\]5148HSS: 72N/ARand et al. \[[@CR36]\]3850N/A48%Springer et al. \[[@CR37]\]6975KSS : 10067%Springer et al. \[[@CR38]\]2659KSS: 10173%Utting and Newman \[[@CR39]\]3036KSS: 10670%Westrich et al. \[[@CR40]\]2433KSS: 12892%*KSS* Knee society clinical score (range: 0--200), *HSS* Hospital for special surgery score (range: 0--100)

Conclusion {#Sec9}
==========

DFR is an established procedure to restore distal femoral integrity. This retrospective analysis confirms the high incidence of implant-related complications and failures in DFR for complex oncological and non-oncological lower limb salvage as already outlined by previous studies with different prosthetic systems. Structural failure, soft tissue problems, and prosthetic joint infections are the complications that surgeons face when implanting DFR, without significant differences in oncologic and non-oncologic patients. Functional and mental outcomes seem to depend mainly on the patients' age at reconstruction, showing significantly better results in younger oncologic patients receiving reconstruction after tumor surgery. Orthopedic surgeons and patients should be aware of potentially high complication rates and age-related functional outcome of this procedure.
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